Platelets, Cardiac Valves and Sulphinpyrazone - Reply

C A Ludlam

doi:10.1055/s-0038-1657164

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1982; 47(02): 189
DOI: 10.1055/s-0038-1657164

Letter to the Editor

Schattauer GmbH Stuttgart

Platelets, Cardiac Valves and Sulphinpyrazone - Reply

C A Ludlam

Department of Haematology, The Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh EH3 9YW, Scotland, U.K.

› Institutsangaben

Abstract

als PDF herunterladen

PDF (246 kb)

Referenzen

References
1 Ludlam CA, Allan N, Blandford RB, Dowdle R, Bentley NJ, Bloom AL. Platelet and coagulation function in patients with abnormal cardiac valves treated with Sulphinpyrazone. Thromb Haemostas 1981; 46: 743-746
2 Barkhan P. Therapeutic range with BCTR (letter). Thromb Haemostas 1976; 35: 751
3 Loeliger EA. The optimal therapeutic range in oral anticoagulation. History and Proposal. Thromb Haemostas 1979; 42: 1141-1152
4 Cohn LH, Mudge GH, Pratter F, Collins JJ. Five to eight-year follow-up of patients undergoing porcine heart-valve replacement. N Eng J Med 1981; 304: 258-262
5 Dale J, Myhre E. Can acetylsalicytic acid alone prevent arterial thromboembolism?. A Pilot study in patients with aortic ball valve prostheses. Acta Med Scand (Suppl. 645) 1981; 73-78
6 Fuster V, Chesebro JH. Systemic thromboemboli in mitral Starr-Edwards prothesis: A longterm followup (10-19 years). Thromb Haemostas (Abstracts) 1981; 46: 288
7 Loeliger EA. Sulphinpyrazone and Thromboembolism (letter). Circulation 1981; 64: 1076-1077
8 Steele P, Rainwater J. Favourable effect of sulphinpyrazone on thromboembolism in patients with rheumatic heart disease. Circulation 1980; 62: 462-465
9 Steele P. Sulphinpyrazone and Thromboembolism (letter). Circulation 1981; 64: 1077
10 Goodnight SH. Antiplatelet Therapy for Mitral Stenosis?. Circulation 1980; 62: 466-468
11 Schmid FR, Witwer MW, Tesar JT. Acute myelomonocytic leukaemia and multiple myeloma after sulphinpyrazone and colchicine treatment of gout. Br Med J 1976; 3: 89